What Bioplus Life Sciences does

Bioplus Life Sciences is a Bengaluru-headquartered, privately-held pharmaceutical and nutraceutical CDMO (Contract Development and Manufacturing Organization) operating across 50+ countries with 78 years of operating history. The company runs three integrated business divisions: Contract Manufacturing Services (CMS) producing tablets, capsules, powders, creams, and gels at high volume; EU/ANZ Pharma Generics distributing private label products (Altifo product family) across European, Australian, and New Zealand markets; and a proprietary nutraceutical portfolio including branded products such as BioDHA (algal DHA from Schizochytrium fermentation), Ketoji (ketone ester supplement), Lactopure (Bacillus coagulans probiotic), Vitamin D3, Vitamin K2, Glucosamine, and a proprietary sucralose manufacturing process. Manufacturing operations are anchored at a 15-acre EU/TGA/Health Canada GMP-certified facility in Hosur, Tamil Nadu, with capacity of 7 billion tablets/year, 630 million capsules/year, 2,000 metric tons of blend/powder, 50,000L fermentation, and 120,000L synthetic chemistry capacity, plus a new 2 million liter microbial fermentation bio foundry under construction.

The company's underlying technology platform spans biotechnology and synthetic chemistry, with proprietary capabilities in metabolic engineering, molecular biology, synthetic biology, precision fermentation, organic synthesis, biocatalysis, and carbohydrate chemistry. It holds multiple international regulatory certifications (MHRA, TGA, Health Canada, WHO GMP, NSF, BRCGS, GRMA, ISO 14001) enabling market access to highly regulated pharmaceutical and dietary supplement markets. Beyond CDMO and generics, the company has advanced two drug programs to Phase 3 ready status targeting global unmet needs in ophthalmology (including pediatric myopia) and other therapeutic areas, signaling a strategic pivot toward proprietary therapeutic development with future licensing/royalty revenue potential.

Bioplus operates a B2B enterprise sales model targeting pharmaceutical companies, dietary supplement brands, and healthcare providers through direct engagement and major industry exhibitions (JP Morgan Healthcare, CPHI, BIO International, Vitafoods). Revenue is generated through contract manufacturing fees, API product sales, EU/ANZ generics distribution, and branded nutraceutical sales. The company is led by Chairman & CEO Sundeep Aurora and Director & CFO Sunjeev Aurora, indicating likely founder/family ownership, with Neha Aurora as Business Unit Head. Only one institutional funding event from AIF Capital in 2008 is recorded, and no external venture or private equity investment is disclosed, suggesting the company has been primarily bootstrapped or self-funded through its operating history.

Name

Bioplus Life Sciences

Legal name

Bioplus Life Sciences Private Limited

Website

https://bioplus.in

Company type

Private

Founded year

1947

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bengaluru-based pharmaceutical CDMO and nutraceutical manufacturer operating in 50+ countries, producing generics, APIs, and branded supplements (BioDHA, Ketoji, Lactopure) from EU GMP-certified facilities, with two Phase 3 ready clinical programs.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Contract pharmaceutical manufacturing
• Nutraceutical product development
• Active pharmaceutical ingredients
• Microbial fermentation services
• EU generic pharmaceuticals

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services (CMS): Full-service CDMO offering manufacturing of tablets, capsules, powders, sachets, liquids, and creams/gels for pharmaceutical and nutraceutical clients. Revenue generated through manufacturing fees based on production volumes and formulation complexity.
2. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of APIs including vitamins (D3, K2), probiotics (Lactopure), glucosamine, BioDHA, sucralose, and ketone supplements. Revenue from product sales to B2B customers.
3. EU/ANZ Pharma Generics: Distribution of generic pharmaceutical products in EU, Australia, New Zealand markets. Revenue from product sales through regulatory-approved channels.
4. Novel Therapeutics Development: Late-stage clinical phase drug development with 2 programs in Phase 3 ready status for global unmet needs in ophthalmology and other therapeutic areas. Future revenue expected from licensing and partnership agreements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Bioplus Life Sciences is a Contract Development and Manufacturing Organization (CDMO) and pharmaceutical products company that develops and manufactures oral solid and liquid dosage forms including tablets, capsules, powders, sachets, liquids, and creams/gels at EU cGMP-compliant facilities in India. The company also produces and sells a proprietary portfolio of nutraceutical APIs and finished products (BioDHA, Ketoji, Lactopure, Vitamin D3/K2, Glucosamine, Vitamin E TPGS, Sucralose) and distributes EU/ANZ pharma generics under the Altifo brand across 50+ countries.

Product overview

Bioplus Life Sciences operates as a CDMO (Contract Development and Manufacturing Organization) with three integrated business divisions: (1) Contract Manufacturing Services (CMS) providing pharmaceutical manufacturing for tablets, capsules, powders, and creams/gels from EU cGMP-compliant facilities; (2) EU/ANZ Pharma Generics offering private label pharmaceutical products; and (3) a proprietary nutraceutical portfolio including branded finished products (Ketoji, Vitamin D3, Vitamin K2, Lactopure, Glucosamine, BioDHA, Vitamin E TPGS, Sucralose) and specialty ingredients (DHA algal oil, DHA microencapsulated powder). The company also maintains an extensive dietary supplements private label portfolio distributed through Nature's Only. The overall offering combines CDMO services with proprietary product brands, serving global markets across pharmaceutical and nutraceutical segments.

Differentiator

Problem solved

Functional benefit

Brands

• BioDHA: Algal DHA omega-3 fatty acid supplement sourced from microalgae Schizochytrium, available as algal oil and powder for beverages, chocolates, ice creams, bakeries, yogurt, and infant food applications
• Ketoji
• Lactopure
• Vitamin E TPGS
• Altifo

Products and services

• Ketoji Ketone ester (D-β-hydroxybutyrate ester) therapeutic supplement designed for weight management, improved cognition, and sustained energy on a low carbohydrate diet, sold as a branded nutraceutical product.
• Vitamin D3 Cholecalciferol (Vitamin D3) supplement API that regulates calcium and phosphorus absorption for bone density, immune defense, and neuromuscular coordination, sold as a B2B ingredient and nutraceutical.
• Vitamin K2 Bone and cardiovascular health API that activates osteocalcin and matrix Gla protein to bind calcium to bones while preventing arterial calcification, marketed as a nutraceutical ingredient.
• Lactopure Bacillus coagulans probiotic supplement with spore-forming capability and GRAS/EFSA QPS status, supporting bone strength, heart health, and calcium regulation.
• Glucosamine Glucosamine sulphate API and supplement for symptomatic relief of mild-to-moderate osteoarthritis, supporting cartilage structure and joint flexibility.
• BioDHA Algal DHA omega-3 fatty acid ingredient sourced from microalgae Schizochytrium via proprietary fermentation, supporting brain development, cognition, and cardiovascular health. Available as algal powder and algal oil.
• Vitamin E TPGS Alpha Tocopheryl Polyethylene Glycol Succinate water-soluble vitamin E formulation used as emulsifier, drug delivery enhancer, and antioxidant in dietary supplements.
• Sucralose High-intensity zero-calorie sweetener manufactured using proprietary technology meeting international standards equivalent to Tate & Lyle specifications.
• Contract Manufacturing Services (CMS) Full-service CDMO offering contract manufacturing of oral dosage forms including tablets (7 billion annually), capsules (630 million annually), powders, sachets, liquids, and creams/gels, executed from EU cGMP-compliant Bangalore facility for pharmaceutical and nutraceutical clients.
• EU/ANZ Pharma Generics (Altifo) Private label generic pharmaceutical products for EU and ANZ markets under the Altifo brand family, including Altifo Basic, Altifo Gold, Altifo HB, Altifo HS, Ambrox, Astrin XS, Astrin Hangover, and Astrin M variants, distributed through regional partners.
• DHA Algal Oil and Microencapsulated Powder Specialty DHA nutraceutical ingredients produced via microbial fermentation: clear DHA algal oil with 40% DHA strength (product code DHA001, peroxide value less than 5.0) and refined DHA microencapsulated powder with 10% DHA content (product code DHA201) for food and supplement applications.
• Dietary Supplements Portfolio Extensive portfolio of branded and private label dietary supplements distributed through Nature's Only, covering joint health (Cartigen series), bone health (Supracal, D-Max), eye health (Optivision), cardiovascular (Kardiol), and probiotics (Lactol).

Quantifiable outcome

• 78 years of operating history demonstrating business stability
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Granules India: Indian pharmaceutical manufacturer with high-volume API and finished dose manufacturing (PFIs, tablets, capsules). Comparable to Bioplus in large-scale generic pharmaceutical manufacturing and multi-format production capabilities.
• Piramal Pharma Solutions: Global CDMO offering drug substance and drug product development and manufacturing services. Comparable to Bioplus in providing integrated CDMO solutions for pharmaceutical and biotech customers.
• Syngene International: Indian contract research and manufacturing services organization offering CDMO capabilities across small molecules and biologics. Comparable to Bioplus in serving global pharma with manufacturing and formulation services.
• Divi's Laboratories: India's leading CDMO with strong API and custom synthesis capabilities. Comparable to Bioplus in offering contract manufacturing, API production, and generic ingredients to global pharmaceutical customers.
• Strides Pharma Science: Indian pharmaceutical company focused on generic finished dosage forms with strong regulated market presence. Comparable to Bioplus in oral solid dosage manufacturing and EU/ANZ market focus.
• Jubilant Pharmova: India-based pharmaceutical company with CDMO, generics, and API businesses. Comparable to Bioplus in combining contract manufacturing services with API production and global generics distribution.

Broad incumbents

• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with global generics and API businesses. Comparable to Bioplus in EU generics distribution and API manufacturing, though at significantly larger scale.
• Biocon: Indian biopharmaceutical company with biologics manufacturing, APIs, and branded formulations. Comparable to Bioplus in fermentation-based bioprocessing (insulin, biologics) and B2B ingredients supply.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with global footprint and significant manufacturing scale. Comparable to Bioplus in generic drug manufacturing, EU market presence, and global distribution network, though at much larger scale.

Regional players

• NATCO Pharma: Indian generic pharmaceutical manufacturer with focus on complex generics and oncology. Comparable to Bioplus in India-based generic manufacturing with export focus to regulated markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bioplus-lifesciences
• Xx.com/BioPlusLifeSci

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioplus Life Sciences